A Look At DaVita (DVA) Valuation As Medicare Rules And Value-Based Kidney Care Progress

Simply Wall St.

Jan 05

DaVita (DVA) is back on investors’ radar after recent Medicare payment rules for end-stage renal disease aligned with expectations, paired with continued growth in risk-bearing and value-based kidney ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601883389"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601883389\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601883389?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","is_english":true,"pubTime":"2026-01-05 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601883389","market":"hk","top_or_hot":-1,"title":"A Look At DaVita (DVA) Valuation As Medicare Rules And Value-Based Kidney Care Progress","media":"Simply Wall St.","content":"<div>\n<p>DaVita (DVA) is back on investors’ radar after recent Medicare payment rules for end-stage renal disease aligned with expectations, paired with continued growth in risk-bearing and value-based kidney ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-dva/davita/news/a-look-at-davita-dva-valuation-as-medicare-rules-and-value-b\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At DaVita (DVA) Valuation As Medicare Rules And Value-Based Kidney Care Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At DaVita (DVA) Valuation As Medicare Rules And Value-Based Kidney Care Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-05 18:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-dva/davita/news/a-look-at-davita-dva-valuation-as-medicare-rules-and-value-b><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DaVita (DVA) is back on investors’ radar after recent Medicare payment rules for end-stage renal disease aligned with expectations, paired with continued growth in risk-bearing and value-based kidney ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-dva/davita/news/a-look-at-davita-dva-valuation-as-medicare-rules-and-value-b\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-dva/davita/news/a-look-at-davita-dva-valuation-as-medicare-rules-and-value-b","article_id":"2601883389","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-dva/davita/news/a-look-at-davita-dva-valuation-as-medicare-rules-and-value-b","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601883389","pubTimestamp":1767608263,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"DaVita (DVA) is back on investors’ radar after recent Medicare payment rules for end-stage renal disease aligned with expectations, paired with continued growth in risk-bearing and value-based kidney care contracts.\nSee our latest analysis for DaVita.\nThe recent Medicare decision and DaVita’s push into value-based kidney care arrive after a softer patch. A 90-day share price return of a 12.61% decline and a 1-year total shareholder return of a 24.43% loss contrast with a 45.48% gain over...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4196":"保健护理服务","BK4588":"碎股","BK4097":"系统软件","BK4585":"ETF&股票定投概念","DVA":"达维塔保健","PRGS":"Progress Software Corporation"},"translate_title":"随着医疗保险规则和基于价值的肾脏护理进展，DaVita(DVA)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVA":1.5,"PRGS":1.5},"content_text":"DaVita (DVA) is back on investors’ radar after recent Medicare payment rules for end-stage renal disease aligned with expectations, paired with continued growth in risk-bearing and value-based kidney care contracts. See our latest analysis for DaVita. The recent Medicare decision and DaVita’s push into value-based kidney care arrive after a softer patch. A 90-day share price return of a 12.61% decline and a 1-year total shareholder return of a 24.43% loss contrast with a 45.48% gain over three years, which suggests long term holders have still seen meaningful value even as near term momentum has cooled. If this kind of policy driven story has your attention, it could be a good moment to widen your watchlist with healthcare stocks that sit at the intersection of care delivery and long term chronic disease trends. With DaVita posting US$13.32b in revenue, US$771.92m in net income and trading at US$114.51, plus some implied upside to analyst targets, you have to ask: is the current price a bargain, or is it already reflecting expectations for future growth? AdvertisementMost Popular Narrative: 20.8% Undervalued With DaVita last closing at US$114.51 against a narrative fair value of US$144.50, the current setup hinges on how earnings and margins evolve from here. The analysts have a consensus price target of $153.5 for DaVita based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $186.0, and the most bearish reporting a price target of just $137.0. Read the complete narrative. Curious what earnings profile and margin shape are baked into that valuation gap? The narrative leans on measured growth, steady profitability, and a future P/E reset that contrasts sharply with the wider US Healthcare group. Result: Fair Value of $144.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the narrative depends on patient mortality normalizing and reimbursement keeping pace with costs, and setbacks on either front could quickly erode the perceived valuation gap. Find out about the key risks to this DaVita narrative.  Build Your Own DaVita Narrative If you see the story differently or want to test your own assumptions against the numbers, you can build and stress test your version in minutes. Do it your way A great starting point for your DaVita research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If DaVita has sparked your interest, do not stop here. Broaden your opportunity set by checking other themes where fundamentals, pricing and long term stories intersect.  Spot potential mispricings by scanning these 868 undervalued stocks based on cash flows that may trade below what their cash flows imply. Ride powerful technology trends by zeroing in on these 25 AI penny stocks shaping the next wave of automation and data driven services. Tap into income potential with these 14 dividend stocks with yields > 3% that could complement more growth focused positions in your portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}